Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma

BACKGROUND: A therapeutic strategy involving combined treatment with lenvatinib plus pembrolizumab (LEP) has demonstrated a relatively high antitumor response in several solid tumors; however, the efficacy and safety of LEP in patients with refractory bile tract carcinoma (BTC) remains unknown. METH...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Hepatobiliary Surg Nutr
Autores principales: Lin, Jianzhen, Yang, Xu, Long, Junyu, Zhao, Songhui, Mao, Jinzhu, Wang, Dongxu, Bai, Yi, Bian, Jin, Zhang, Lei, Yang, Xiaobo, Wang, Anqiang, Xie, Fucun, Shi, Weiwei, Yang, Huayu, Pan, Jie, Hu, Ke, Guan, Mei, Zhao, Lin, Huo, Li, Mao, Yilei, Sang, Xinting, Wang, Kai, Zhao, Haitao
Formato: Artigo
Lenguaje:Inglês
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7423565/
https://ncbi.nlm.nih.gov/pubmed/32832493
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/hbsn-20-338
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares